{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:02Z","timestamp":1789154402545,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"DOI":"10.7759\/cureus.78812","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:37:07Z","timestamp":1739194627000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Cutaneous Adverse Reaction to Lamotrigine: A Case of Stevens-Johnson Syndrome in a Psychiatric Patient"],"prefix":"10.7759","author":[{"given":"Kajomi","family":"Shingala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Nariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli EP","year":"2018","unstructured":"Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018, 59:2318-24. 10.1111\/epi.14591","journal-title":"Epilepsia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pb.2021.51.2.96","article-title":"Lamotrigine and Stevens-Johnson syndrome prevention","volume":"16","author":"Edinoff AN","year":"2021","unstructured":"Edinoff AN, Nguyen LH, Fitz-Gerald MJ, et al.. Lamotrigine and Stevens-Johnson syndrome prevention. Psychopharmacol Bull. 2021, 16:96-114. 10.1176\/appi.pb.2021.51.2.96","journal-title":"Psychopharmacol Bull"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2015.01.002","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013","volume":"64","author":"Abe J","year":"2015","unstructured":"Abe J, Mataki K, Umetsu R, et al.. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013. Allergol Int. 2015, 64:277-9. 10.1016\/j.alit.2015.01.002","journal-title":"Allergol Int"},{"key":"ref4","unstructured":"Drug label. 020241s064. (2021). Accessed: 2024 Dec 6: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022251,020764s029,020241s036lbl.pdf."},{"key":"ref5","unstructured":"Drug label. 021710s11s012. (2016). Accessed: 2025 Jan 30: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021710s11s012lbl.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1586\/ern.13.50","article-title":"Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease","volume":"13","author":"M\u00fcller T","year":"2013","unstructured":"M\u00fcller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease. Expert Rev Neurother. 2013, 13:707-18. 10.1586\/ern.13.50","journal-title":"Expert Rev Neurother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/TME.0000000000000197","article-title":"Stevens-Johnson syndrome: a challenging diagnosis","volume":"40","author":"Davis WD","year":"2018","unstructured":"Davis WD, Schafer PA. Stevens-Johnson syndrome: a challenging diagnosis. Adv Emerg Nurs J. 2018, 40:176-82. 10.1097\/TME.0000000000000197","journal-title":"Adv Emerg Nurs J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung WH","year":"2008","unstructured":"Chung WH, Hung SI, Yang JY, et al.. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008, 14:1343-50. 10.1038\/nm.1884","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60956-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko E","year":"2005","unstructured":"Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005, 94:419-36. 10.1016\/S1081-1206(10)60956-0","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.11.004","article-title":"Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients","volume":"70","author":"Watanabe T","year":"2021","unstructured":"Watanabe T, Go H, Saigusa Y, et al.. Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients. Allergol Int. 2021, 70:229-34. 10.1016\/j.alit.2020.11.004","journal-title":"Allergol Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.77","article-title":"Pharmacogenetics of drug hypersensitivity","volume":"11","author":"Phillips EJ","year":"2010","unstructured":"Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2010, 11:973-87. 10.2217\/pgs.10.77","journal-title":"Pharmacogenomics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann S","year":"2017","unstructured":"Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017, 153:514-22. 10.1001\/jamadermatol.2016.5668","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang CW","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, et al.. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018, 128:985-96. 10.1172\/JCI93349","journal-title":"J Clin Invest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340881-severe-cutaneous-adverse-reaction-to-lamotrigine-a-case-of-stevens-johnson-syndrome-in-a-psychiatric-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:37:10Z","timestamp":1739194630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340881-severe-cutaneous-adverse-reaction-to-lamotrigine-a-case-of-stevens-johnson-syndrome-in-a-psychiatric-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.78812","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}